Avoidance of Tetracyclines for Group A Streptococcal Pharyngitis and Preferred Therapies

Resistance and Guideline Recommendations Against Tetracyclines

Tetracyclines (including doxycycline) are contraindicated for Group A Streptococcus (GAS) pharyngitis because resistance rates range from 24 % to 74 % across studies, and clinical failure to eradicate even susceptible organisms is common. [IDSA strong recommendation] [1][2]
The Infectious Diseases Society of America (IDSA) explicitly recommends that tetracyclines not be used for GAS pharyngitis due to high resistance and frequent eradication failure; this prohibition is equivalent to the ban on sulfonamides (e.g., Bactrim) for the same indication. [IDSA strong recommendation] [1][2]

Penicillin V or amoxicillin are the drugs of choice for GAS pharyngitis because no penicillin resistance has been documented worldwide, and they are the only agents proven in controlled trials to prevent acute rheumatic fever. [IDSA strong recommendation] [1][2]
Adult regimen: Penicillin V 500 mg orally twice daily for 10 days or amoxicillin 500 mg orally twice daily for 10 days. [1][2]

When methicillin‑resistant Staphylococcus aureus (MRSA) is suspected in skin and soft‑tissue infections, doxycycline may be employed, but its activity against beta‑hemolytic streptococci is not well defined. [IDSA moderate recommendation] 3
For purulent cellulitis with suspected MRSA, doxycycline 100 mg twice daily is an acceptable option; however, the IDSA notes that the efficacy of doxycycline (as well as TMP‑SMX and minocycline) against beta‑hemolytic streptococci remains uncertain. [IDSA moderate recommendation] 3

The Infectious Diseases Society of America guidelines recommend that sulfonamides are not used for treatment of group A streptococcal pharyngitis due to higher rates of resistance and frequent failure to eradicate susceptible organisms from the pharynx 4, 5
Penicillin V remains the treatment of choice for Group A Streptococcus infections because of its proven efficacy, safety, narrow spectrum, and low cost, with no documented penicillin resistance in Group A Streptococcus anywhere in the world 4, 5
The American Academy of Pediatrics and other guideline societies support the use of penicillin V, with dosing of 250 mg 2-3 times daily for children and 250 mg 3-4 times daily or 500 mg twice daily for 10 days for adolescents and adults 6, 7

For penicillin-allergic patients with non-immediate allergy, first-generation cephalosporins like cephalexin 500 mg twice daily for 10 days are preferred 6, 8
For patients with immediate or anaphylactic allergy to penicillin, clindamycin 300 mg three times daily for 10 days is the preferred choice, with only ~1% resistance in the United States 6, 8
Azithromycin 500 mg daily for 5 days is an acceptable alternative, but has 5-8% macrolide resistance rates 6, 8

All antibiotics except azithromycin require a full 10-day course to achieve maximal pharyngeal eradication of Group A Streptococcus and prevent acute rheumatic fever 4, 5, 8
Shortening the course dramatically increases treatment failure and rheumatic fever risk 8